AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02925546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API without SLS and hypermellose (Tablet A)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
Study NCT02136927 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference1210
Study NCT03449342 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Patients will receive standard prophylaxis treatment and treatment of bleeding episodes, according to label. Trial product will be administered as intravenous injections (i.v.)
Study NCT01878708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-L-asparaginase
Study NCT01878708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate
Description: -dexamethasone 40mg daily for 4 days with every cycle.
Study NCT02925546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2798745 Micronized API with SLS and hypermellose (Tablet B)
Description: This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
Study NCT04441255 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-788
Description: TAK-788 Capsule.
Study NCT01607697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: Mindfulness Training
Study NCT04213235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: The participants will receive the written exercise guidebook and a counselling by kinesiologist. Moreover, they will be instructed how to increase their physical activity level.
Study NCT03793517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
Study NCT03793517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY and ATG
Description: Ara-C 4 g·m-2·d-1 intravenously on days -10 to -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3 ATG (2.5 mg·kg-1·d-1) intravenously on days -5 to -2
Study NCT03793517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mBU/CY
Description: hydroxycarbamide (80 mg·kg-1) orally on day -10 Ara-C (2 g·m-2·d-1) on day -9 Busulfan (BU 3.2 mg·kg-1·d-1) intravenously on days -8 to -6, Cyclophosphamide (CY 1.8 g·m-2·d-1) intravenously on days -5 to -4 Simustine (Me-CCNU, 250 mg·m-2) orally once on day -3
Study NCT01986179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Interpretation
Description: Professional interpretation provided over the phone by a national network of certified medical interpreters
Study NCT01986179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Interpretation
Description: Professional interpretation provided over video by a national network of certified medical interpreters
Study NCT01376076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
Study NCT03546114 — intervention group
Intervention type: OTHER
Intervention: Gender Questionnaire
Description: 13-items questionnaire including demographics questions (gender, age, education; naive to osteopathic treatment or not; general gender preferences; specific gender preference in case of low back pain, neck pain, gastrointestinal disorders, musculoskeletal disorders of upper and lower limbs pain; headache; urogenital disorders
Study NCT01238302 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional arthroscopic rotator cuff repair
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.
Study NCT01238302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with PRP
Description: * Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.~* The surgical area was prepared and draped with Betadine.~* Small stab incisions were made in the creation of 4-5 portals as needed.~* A scope was explored via the arthroscopic portal into the GH joint \& subacromial space.~* Repair of full thickness rotator cuff tear was done with suture anchors.~* After tying sutures of the medial row, PRP gels were applied on the repair site.~* The lateral row was secured using suture anchors.~* The skin was closed with Nylon or medical staples.~* Sterile dressing was applied on surgical wound.
Study NCT01376076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone/Moxifloxacin
Description: Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
Study NCT01376076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone/Moxifloxacin
Description: Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
Study NCT03759795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTr (Acceptance and Commitment Training)
Description: The programme is based on Acceptance and Commitment Training (ACT), a contemporary, empirically supported approach to psychological well-being.
Study NCT02976909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel+Cisplatin+5fluorouracil
Description: Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: Audio processor SONNET
Description: AI - N/A, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: SONNET 2: Configuration 1
Description: AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Mild, TNR - Mild
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: SONNET 2: Configuration 2
Description: AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Strong, TNR - Strong
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: SONNET 2: Configuration 3
Description: AI - Mild, WNR - Mild, Beam-former - Auto (NAT), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Mild), TNR - Auto (Off-Mild)
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: SONNET 2: Configuration 4
Description: AI - Strong, WNR - Strong, Beam-former - Auto (OMNI-ABF), AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - Auto (Off-Strong), TNR - Auto (Off-Strong)
Study NCT02628561 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Study NCT02628561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Study NCT02628561 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Study NCT02628561 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Study NCT02628561 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy
Study NCT02628561 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Constraint-Induced Movement Therapy
Study NCT03197376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumosil
Description: 10-Valent Pneumococcal Conjugate Vaccine
Study NCT03197376 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
Study NCT04202887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Fentanyl
Description: 10ml bolus: bupivacaine 0.1% + 25mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 1mcg/ml
Study NCT04202887 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Fentanyl
Description: 10ml bolus: bupivacaine 0.1% + 100mcg fentanyl, followed by a solution of bupivacaine 0.083% + fentanyl 2mcg/ml
Study NCT04202887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric Ultrasonography
Description: The Gastric US will be performed using a portable device with an abdominal probe by the same operator (EF) for all women. The Cross Sectional Area (CSA) of the antrum will be measured in the supine position with the head elevated 45 degrees. CSA will be calculated using the formula (AP x CC x pi)/4, where AC is the anterio-posterior diameter and CC the cranio-caudal diameter. Three consecutive measurements will be performed and the average of the three will be used as the final data. The cutoff used to define a full stomach will be a CSA above 381 mm2, which has been validated in previous studies on laboring woman. Gastric US will be performed immediately after verification of effective epidural analgesia (T0) and intrapartum, two hours after the first measurement (T2h), corresponding to a cumulative dose of 37-97mcg fentanyl in Group LF and 124-240mcg fentanyl in Group HF.
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: SONNET 2: OPUS 2 configuration
Description: AI - Off, WNR - Off, Beam-former - OMNI, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
Study NCT03861442 — intervention group
Intervention type: DEVICE
Intervention: SONNET 2: SONNET configuration
Description: AI - Off, WNR - Mild, Beam-former - NAT, AGC Compression - 3:1, AGC Sensitivity - 75%, ANR - N/A, TNR - N/A
Study NCT04083287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block (Group E)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study NCT04083287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalen brachial plexus block (Group I)
Description: Patients will be administered A 400 mg dose of ibuprofen every 8 hours in the postoperative period. A patient controlled device prepared with 10 mcg/ ml fentanyl will be attached to all patients with a protocol included 10 mcg bolus without infusion dose, 10 min lockout time and 4 hour limit.~Postoperative pain assessment will be performed using the VAS score (0 = no pain, 10 = the most severe pain felt). The VAS scores at rest and during cough will be recorded at postoperative 1, 2, 4, 8, 16, 24 and 48 hours. If the VAS score will be ≥ 4, 0.5 mg/ kg meperidine IV will be administered. Sedation level will be assessed with a 4-point sedation scale (0 = awake, eyes open, 1 = sleepy but responding to verbal stimulus, 2 = sleepy and hard to evoke, 3 = sleepy, not aroused by shaking). The first time of the use of rescue analgesic, intraoperative and postoperative opioid consumption, side effects such as nausea, vomiting, itching and block related complications will be recorded.
Study NCT02777294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online intervention
Description: Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
Study NCT02777294 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-educational website
Description: Psycho-educational self-help website about rape-related PTSD
Study NCT02999295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab (8 mg/kg) is administered.
Study NCT02999295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
Study NCT01269138 — intervention group
Intervention type: DRUG
Intervention: plasma derived Factor VII
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study NCT01269138 — intervention group
Intervention type: DRUG
Intervention: recombinant FVIIa
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study NCT01269138 — intervention group
Intervention type: DRUG
Intervention: Fresh Frozen Plasma
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study NCT01269138 — intervention group
Intervention type: DRUG
Intervention: Activated Prothrombin Complex Concentrates
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study NCT01269138 — intervention group
Intervention type: DRUG
Intervention: Virus Inactivated plasma
Description: Treatment of bleeding episodes,treatment during surgery and prophylaxis
Study NCT04302233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New pharmaceutical support (NPS)
Description: The only difference between these 2 groups is that patients in the NPS group benefit from additional visual and oral information on the characteristics of their implant and on medical device vigilance during their hospitalization.
Study NCT04358224 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Dupilumab Prefilled Syringe
Description: open-label
Study NCT02322970 — intervention group
Intervention type: DEVICE
Intervention: transcranial Doppler
Description: Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
Study NCT03301298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: Oral capsule
Study NCT03301298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo given as oral capsule.
Study NCT02410239 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Study NCT02978833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Study NCT03793764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP block
Description: USG guided TAP block
Study NCT03793764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL block
Description: USG guided QL block
Study NCT02978833 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Whole Blood
Study NCT02978833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Study NCT02937558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Description: Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
Study NCT02937558 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline
Study NCT04357483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flowable thrombin containing collagen hemostat matrix
Description: A 5 ml flowable hemostat matrix (CollaStat®) was applied to the stump or anastomosis site after pancreatectomy.
Study NCT04357483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thrombin coated L-dopa contained collagen patch
Description: A 5x2.5cm sized thrombin coated L-dopa contained collagen patch (CollaSeal®) was applied to the stump or anastomosis site after pancreatectomy.
Study NCT04632316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-Fludarabine (Cy/Flu)
Description: Lymphodepleting conditioning regimen
Study NCT04632316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oNKord®
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Study NCT02315534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide.
Study NCT02315534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m\^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m\^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m\^2.
Study NCT02590211 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cognitive, emotional and clinical assessment
Description: Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
Study NCT00658463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
Study NCT00658463 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02451462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00603122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ascent protocol
Description: ascent protocol for the two groups has different acclimatization time
Study NCT00603122 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ascent protocol
Description: ascent protocol for the two groups has different acclimatization time
Study NCT03256604 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: left-over sputum
Description: Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
Study NCT01336153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC601
Description: group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
Study NCT01336153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
Study NCT00825903 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
Study NCT04193592 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone will be titrated over 14 days, as tolerated, to the full dose of 2403 mg per day, as follows: Days 1 - 7: one capsule TID; Days 8 - 14: two capsules TID; Days 15 to week 52: three capsules TID. Dose may be reduced to manage an adverse event.
Study NCT01907425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Study NCT02048085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
Study NCT02048085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD